C4 Therapeutics Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 18.0% | 51.9% | 66.7% | 17.0% | 13.4% | 34.1% | 27.8% | 32.2% | – | 16.4% | 29.3% | – | – | |
| 82.0% | 48.1% | 100.0% | 83.0% | 86.6% | 65.9% | 100.0% | 100.0% | 100.0% | 100.0% | 70.7% | 100.0% | 94.9% | |
| 256.0% | 932.0% | 741.5% | 197.8% | 207.3% | 628.0% | 374.0% | 405.3% | 231.4% | 226.8% | 400.0% | 368.5% | 285.5% | |
| 95.1% | 315.8% | 338.5% | 80.8% | 76.6% | 200.4% | 128.9% | 135.6% | 79.4% | 83.3% | 151.7% | 129.4% | 102.8% | |
| 333.1% | 1,195.9% | 1,160.2% | 261.6% | 270.5% | 794.3% | 502.9% | 541.0% | 406.4% | 310.1% | 522.4% | 497.9% | 413.8% | |
| -251.2% | -1,147.7% | -1,060.2% | -178.6% | -183.9% | -728.4% | -402.9% | -441.0% | -306.4% | -210.1% | -451.6% | -397.9% | -319.0% | |
| 1.5% | 74.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| -235.1% | -1,057.3% | -933.2% | -147.6% | -160.6% | -665.3% | -363.7% | -402.6% | -286.4% | -184.9% | -408.5% | -355.9% | -289.1% | |
| 9.1% | 8.5% | -66.7% | -17.0% | -13.4% | 2.5% | – | – | – | 1.1% | – | – | – | |
| -244.2% | -1,065.7% | -933.2% | -147.6% | -160.6% | -667.8% | -363.7% | -402.6% | -286.4% | -186.0% | -408.5% | -355.9% | -289.4% | |
| -215.6% | -1,005.4% | -965.3% | -130.5% | -147.2% | -631.2% | -357.4% | -393.1% | -282.3% | -181.0% | -379.2% | -351.5% | -280.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.